Pharmacological Identification of a Guanidine-Containing β-Alanine Analogue with Low Micromolar Potency and Selectivity for the Betaine/GABA Transporter 1 (BGT1)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Pharmacological Identification of a Guanidine-Containing β-Alanine Analogue with Low Micromolar Potency and Selectivity for the Betaine/GABA Transporter 1 (BGT1). / Al-Khawaja, Anas Mohammad Ali; Petersen, Jette Gellert; Damgaard, Maria; Jensen, Mette Høgh; Vogensen, Stine Byskov; Lie, Maria Elena Klibo; Kragholm, Bolette; Bräuner-Osborne, Hans; Clausen, Rasmus Prætorius; Frølund, Bente; Wellendorph, Petrine.

I: Neurochemical Research, Bind 39, Nr. 10, 23.05.2014, s. 1988-1996.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Al-Khawaja, AMA, Petersen, JG, Damgaard, M, Jensen, MH, Vogensen, SB, Lie, MEK, Kragholm, B, Bräuner-Osborne, H, Clausen, RP, Frølund, B & Wellendorph, P 2014, 'Pharmacological Identification of a Guanidine-Containing β-Alanine Analogue with Low Micromolar Potency and Selectivity for the Betaine/GABA Transporter 1 (BGT1)', Neurochemical Research, bind 39, nr. 10, s. 1988-1996. https://doi.org/10.1007/s11064-014-1336-9

APA

Al-Khawaja, A. M. A., Petersen, J. G., Damgaard, M., Jensen, M. H., Vogensen, S. B., Lie, M. E. K., ... Wellendorph, P. (2014). Pharmacological Identification of a Guanidine-Containing β-Alanine Analogue with Low Micromolar Potency and Selectivity for the Betaine/GABA Transporter 1 (BGT1). Neurochemical Research, 39(10), 1988-1996. https://doi.org/10.1007/s11064-014-1336-9

Vancouver

Al-Khawaja AMA, Petersen JG, Damgaard M, Jensen MH, Vogensen SB, Lie MEK o.a. Pharmacological Identification of a Guanidine-Containing β-Alanine Analogue with Low Micromolar Potency and Selectivity for the Betaine/GABA Transporter 1 (BGT1). Neurochemical Research. 2014 maj 23;39(10):1988-1996. https://doi.org/10.1007/s11064-014-1336-9

Author

Al-Khawaja, Anas Mohammad Ali ; Petersen, Jette Gellert ; Damgaard, Maria ; Jensen, Mette Høgh ; Vogensen, Stine Byskov ; Lie, Maria Elena Klibo ; Kragholm, Bolette ; Bräuner-Osborne, Hans ; Clausen, Rasmus Prætorius ; Frølund, Bente ; Wellendorph, Petrine. / Pharmacological Identification of a Guanidine-Containing β-Alanine Analogue with Low Micromolar Potency and Selectivity for the Betaine/GABA Transporter 1 (BGT1). I: Neurochemical Research. 2014 ; Bind 39, Nr. 10. s. 1988-1996.

Bibtex

@article{dca5c7bafedd44d792e66a55d576ed07,
title = "Pharmacological Identification of a Guanidine-Containing β-Alanine Analogue with Low Micromolar Potency and Selectivity for the Betaine/GABA Transporter 1 (BGT1)",
abstract = "The γ-aminobutyric acid (GABA) transporters (GATs) are key membrane transporter proteins involved in the termination of GABAergic signaling at synapses in the mammalian brain and proposed drug targets in neurological disorders such as epilepsy. To date, four different GAT subtypes have been identified: GAT1, GAT2, GAT3 and the betaine/GABA transporter 1 (BGT1). Owing to the lack of potent and subtype selective inhibitors of the non-GAT1 GABA transporters, the physiological role and therapeutic potential of these transporters remain to be fully understood. Based on bioisosteric replacement of the amino group in β-alanine or GABA, a series of compounds was generated, and their pharmacological activity assessed at human GAT subtypes. Using a cell-based [(3)H]GABA uptake assay, several selective inhibitors at human BGT1 were identified. The guanidine-containing compound 9 (2-amino-1,4,5,6-tetrahydropyrimidine-5-carboxylic acid hydrochloride) displayed more than 250 times greater potency than the parent compound β-alanine at BGT1 and is thus the most potent inhibitor reported to date for this subtype (IC50 value of 2.5 µM). In addition, compound 9 displayed about 400, 16 and 40 times lower inhibitory potency at GAT1, GAT2 and GAT3, respectively. Compound 9 was shown to be a substrate for BGT1 and to have an overall similar pharmacological profile at the mouse orthologue. Compound 9 constitutes an interesting pharmacological tool for specifically investigating the cellular pharmacology of BGT1 and is the first small-molecule substrate identified with such a high selectivity for BGT1 over the three other GAT subtypes.",
author = "Al-Khawaja, {Anas Mohammad Ali} and Petersen, {Jette Gellert} and Maria Damgaard and Jensen, {Mette H{\o}gh} and Vogensen, {Stine Byskov} and Lie, {Maria Elena Klibo} and Bolette Kragholm and Hans Br{\"a}uner-Osborne and Clausen, {Rasmus Pr{\ae}torius} and Bente Fr{\o}lund and Petrine Wellendorph",
year = "2014",
month = "5",
day = "23",
doi = "10.1007/s11064-014-1336-9",
language = "English",
volume = "39",
pages = "1988--1996",
journal = "Neurochemical Research",
issn = "0364-3190",
publisher = "Springer",
number = "10",

}

RIS

TY - JOUR

T1 - Pharmacological Identification of a Guanidine-Containing β-Alanine Analogue with Low Micromolar Potency and Selectivity for the Betaine/GABA Transporter 1 (BGT1)

AU - Al-Khawaja, Anas Mohammad Ali

AU - Petersen, Jette Gellert

AU - Damgaard, Maria

AU - Jensen, Mette Høgh

AU - Vogensen, Stine Byskov

AU - Lie, Maria Elena Klibo

AU - Kragholm, Bolette

AU - Bräuner-Osborne, Hans

AU - Clausen, Rasmus Prætorius

AU - Frølund, Bente

AU - Wellendorph, Petrine

PY - 2014/5/23

Y1 - 2014/5/23

N2 - The γ-aminobutyric acid (GABA) transporters (GATs) are key membrane transporter proteins involved in the termination of GABAergic signaling at synapses in the mammalian brain and proposed drug targets in neurological disorders such as epilepsy. To date, four different GAT subtypes have been identified: GAT1, GAT2, GAT3 and the betaine/GABA transporter 1 (BGT1). Owing to the lack of potent and subtype selective inhibitors of the non-GAT1 GABA transporters, the physiological role and therapeutic potential of these transporters remain to be fully understood. Based on bioisosteric replacement of the amino group in β-alanine or GABA, a series of compounds was generated, and their pharmacological activity assessed at human GAT subtypes. Using a cell-based [(3)H]GABA uptake assay, several selective inhibitors at human BGT1 were identified. The guanidine-containing compound 9 (2-amino-1,4,5,6-tetrahydropyrimidine-5-carboxylic acid hydrochloride) displayed more than 250 times greater potency than the parent compound β-alanine at BGT1 and is thus the most potent inhibitor reported to date for this subtype (IC50 value of 2.5 µM). In addition, compound 9 displayed about 400, 16 and 40 times lower inhibitory potency at GAT1, GAT2 and GAT3, respectively. Compound 9 was shown to be a substrate for BGT1 and to have an overall similar pharmacological profile at the mouse orthologue. Compound 9 constitutes an interesting pharmacological tool for specifically investigating the cellular pharmacology of BGT1 and is the first small-molecule substrate identified with such a high selectivity for BGT1 over the three other GAT subtypes.

AB - The γ-aminobutyric acid (GABA) transporters (GATs) are key membrane transporter proteins involved in the termination of GABAergic signaling at synapses in the mammalian brain and proposed drug targets in neurological disorders such as epilepsy. To date, four different GAT subtypes have been identified: GAT1, GAT2, GAT3 and the betaine/GABA transporter 1 (BGT1). Owing to the lack of potent and subtype selective inhibitors of the non-GAT1 GABA transporters, the physiological role and therapeutic potential of these transporters remain to be fully understood. Based on bioisosteric replacement of the amino group in β-alanine or GABA, a series of compounds was generated, and their pharmacological activity assessed at human GAT subtypes. Using a cell-based [(3)H]GABA uptake assay, several selective inhibitors at human BGT1 were identified. The guanidine-containing compound 9 (2-amino-1,4,5,6-tetrahydropyrimidine-5-carboxylic acid hydrochloride) displayed more than 250 times greater potency than the parent compound β-alanine at BGT1 and is thus the most potent inhibitor reported to date for this subtype (IC50 value of 2.5 µM). In addition, compound 9 displayed about 400, 16 and 40 times lower inhibitory potency at GAT1, GAT2 and GAT3, respectively. Compound 9 was shown to be a substrate for BGT1 and to have an overall similar pharmacological profile at the mouse orthologue. Compound 9 constitutes an interesting pharmacological tool for specifically investigating the cellular pharmacology of BGT1 and is the first small-molecule substrate identified with such a high selectivity for BGT1 over the three other GAT subtypes.

U2 - 10.1007/s11064-014-1336-9

DO - 10.1007/s11064-014-1336-9

M3 - Journal article

C2 - 24852577

VL - 39

SP - 1988

EP - 1996

JO - Neurochemical Research

JF - Neurochemical Research

SN - 0364-3190

IS - 10

ER -

ID: 122440073